For the quarter ending 2026-03-31, WST made $844,900K in revenue. $138,800K in net income. Net profit margin of 16.43%.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net sales | 844,900 | 805,000 | 804,600 | 766,500 |
| Cost of goods and services sold | 548,500 | 501,100 | 510,300 | 492,600 |
| Gross profit | 296,400 | 303,900 | 294,300 | 273,900 |
| Research and development | 15,800 | 21,800 | 17,100 | 19,100 |
| Selling, general and administrative expenses | 99,500 | 107,000 | 102,700 | 95,900 |
| Severance and benefits | - | 5,750* | - | - |
| Asset-related charges | - | 1,350* | - | - |
| Total restructuring and related charges | - | 7,100 | - | - |
| Asset impairments | - | 6,800* | - | - |
| Foreign exchange transaction losses | - | -2,800 | - | - |
| Contingent consideration | - | 1,400 | - | - |
| Loss on disposal of plant | - | 0* | - | - |
| Other items | - | -400 | - | - |
| Other expense (income) (note 14) | -4,000 | -18,500 | -6,900 | -5,200 |
| Operating profit | 177,100 | 156,600 | 167,600 | 153,700 |
| Interest expense, net | 1,900 | -200 | 200 | 100 |
| Interest income | 5,100 | 5,100 | 4,700 | 3,600 |
| Other nonoperating expense (income) | -200 | -400 | -200 | -200 |
| Income before income taxes and equity in net income of affiliated companies | 180,100 | 161,500 | 171,900 | 157,000 |
| Income tax expense | 44,700 | 33,300 | 34,000 | 30,200 |
| Equity in net income of affiliated companies | 3,400 | 3,900 | 2,100 | 5,000 |
| Net income | 138,800 | 132,100 | 140,000 | 131,800 |
| Basic EPS | 1.93 | 1.827 | 1.94 | 1.82 |
| Diluted EPS | 1.92 | 1.817 | 1.92 | 1.82 |
| Basic Average Shares | 72,000,000 | 72,300,000 | 72,200,000 | 72,200,000 |
| Diluted Average Shares | 72,400,000 | 72,700,000 | 72,600,000 | 72,500,000 |
WEST PHARMACEUTICAL SERVICES INC (WST)
WEST PHARMACEUTICAL SERVICES INC (WST)